Patents Assigned to Institut Pasteur
  • Nanobodies suitable for neuron regeneration therapy
    Patent number: 10640552
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e.g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: May 5, 2020
    Assignees: Institut Pasteur, Centre National de la Recherche Scientifique
    Inventors: Christophe Prehaud, Monique Lafon, Pierre Lafaye
  • Monoclonal antibodies specific for serogroup X of and uses thereof in diagnosis
    Patent number: 10613085
    Abstract: The present invention is directed to monoclonal antibodies and antigen-binding portions thereof, specific for the capsular polysaccharides of Neisseria meningitidis serogroup X (NmX), wherein said antibodies or portions thereof are characterized by the sequences of the 6 CDR of the variable regions of the heavy and light chains. These antibodies are suitable for in vitro detection of Neisseria meningitidis serogroup X especially in a biological sample without purification of the capsular polysaccharides. The invention also concerns said monoclonal antibodiesor adequate portions thereofin different diagnostic tests and methods, in order to detect NmX. The invention discloses also a rapid diagnostic test for detecting NmX in a biological fluid.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: April 7, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Muhamed-Kheir Taha, Alain Agnememel
  • Lentiviral vector-based Japanese encephalitis immunogenic composition
    Patent number: 10603374
    Abstract: The present invention relates to a lentiviral vector-based Japanese encephalitis (JE) immunogenic composition. The present invention is directed to a recombinant lentiviral vector expressing the precursor of membrane (prM) and the envelope (E) protein, in particular glycoprotein of a Japanese encephalitis virus (JEV) or immunogenic fragments thereof. The present invention also provides cells expressing the lentiviral vector, uses and methods to prevent a JEV infection in a mammalian host, especially in a human or an animal host, in particular a pig or a piglet, preferably a domestic pig or a domestic piglet.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 31, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Pierre Charneau, Philippe Despres, Melissanne De Wispelaere, Philippe Souque, Marie-Pascale Frenkiel
  • RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS
    Publication number: 20200095607
    Abstract: The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
    Type: Application
    Filed: November 18, 2019
    Publication date: March 26, 2020
    Applicants: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic TANGY, Clarisse LORIN, Lucile MOLLET, Frederic DELEBECQUE
  • In vitro blood-brain barrier model
    Patent number: 10591466
    Abstract: The invention is in the domain of delivery of molecules to brain cells across the blood-brain barrier. The invention relates to a novel polypeptide-based carrier that allows the efficient delivery of an effector peptide, to neuron cells across the blood-brain barrier, and to methods for the production and testing of such carrier, including a model for testing the capacity of such molecule to cross the blood-brain barrier and/or the toxicity of molecules on the blood brain barrier and/or the capacity of molecules that have crossed to target human brain cells (e/g. neurons, astrocytes and microglial cells).
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: March 17, 2020
    Assignees: INSTITUT PASTEUR, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
    Inventors: Christophe Prehaud, Monique Lafon, Pierre-Emmanuel Ceccaldi, Philippe Afonso, Pierre Lafaye
  • Mitochondrial non-coding RNAs for predicting disease progression in heart failure and myocardial infarction patients
    Patent number: 10584383
    Abstract: The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: March 10, 2020
    Assignees: MEDIZINISCHE HOCHSCHULE HANNOVER, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM), UNIVERSITÉ DE LILLE 2 (LILLE 2)—UNIVERSITY OF LAW AND HEALTH, CENTRE HOSPITALIER UNIVERSITAIRE LILLE (CHU), INSTITUT PASTEUR DE LILLE (IPL)
    Inventors: Thomas Thum, Regalla Kumarswamy, Florence Pinet, Christophe Bauters, Pascal De Groote
  • OB-fold used as scaffold for engineering new specific binders
    Patent number: 10584330
    Abstract: The present invention pertains to the field of protein engineering, and provides means for obtaining stable molecules that specifically bind to a target selected amongst a large variety of ligands families. In particular, the present invention provides methods for obtaining a molecule specifically binding to a target of interest, through a combinatorial mutation/selection approach with an OB-fold protein as a starting molecule. In particular, the target of interest can be of a different chemical nature form that of the native target of the OB-fold protein used as the starting molecule.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: March 10, 2020
    Assignees: INSTITUT PASTEUR, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Frederic Pecorari, Pedro Alzari
  • OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
    Publication number: 20200040346
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Application
    Filed: July 31, 2019
    Publication date: February 6, 2020
    Applicants: Eligo Bioscience, Institut Pasteur
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Methods of treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic modulators
    Patent number: 10537537
    Abstract: Methods of treating acute and chronic inflammatory conditions, tissue transplant rejection, and/or organ transplant rejection comprising administering to a subject in need thereof a therapeutically effective amount of a pluripotent anti-inflammatory and metabolic modulators optionally in combination with one or more secondary therapeutic agents and pharmaceutical compositions thereof.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: January 21, 2020
    Assignees: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Marcelo Hill, Mercedes Segovia
  • Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
    Patent number: 10538582
    Abstract: The present invention relates to variable domains of a camelid heavy-chain antibodies directed against a phosphorylated tau protein and conjugates thereof. The present invention also relates to the use of these domains or conjugates for treating or diagnosing disorders mediated by neurofibrillary tangles, neuropil threads or dystrophic neurites, such as tauopathies.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: January 21, 2020
    Assignees: F. HOFFMANN-LA ROCHE AG, INSTITUT PASTEUR, COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Pierre Lafaye, Sylvie Bay, Benoit Delatour, Marc Dhenain, Charles Duyckaerts, Tengfei Li, Matthias Vandesquille, Christian Czech, Fiona Grueninger
  • 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
    Patent number: 10493046
    Abstract: The present invention relates to the field of muscle regeneration, and more particularly to the replenishment of the in vivo muscle stem cells pool. It more specifically relates to a 5-hydroxytryptamine B1 receptor-stimulating agent, and to a composition comprising said agent, for use as i) a promoter of satellite cells self-renewal and/or differentiation, and/or ii) an agent preventing and/or inhibiting the satellite cells pool exhaustion. The invention further encompasses therapeutic and screening methods.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: December 3, 2019
    Assignees: UNIVERSITE PARIS DESCARTES, CENTRE HOSPITALIER SAINTE ANNE PARIS, INSTITUT GUSTAVE-ROUSSY, INSTITUT PASTEUR
    Inventors: Fabrice Bruno Chretien, Raphael Gaillard, Pierre Rocheteau, Olivier Mir
  • NITROALKENE NON STEROIDAL ANTI-INFLAMMATORY DRUGS (NA-NSAIDS) AND METHODS OF TREATING INFLAMMATION RELATED CONDITIONS
    Publication number: 20190359552
    Abstract: Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.
    Type: Application
    Filed: August 7, 2019
    Publication date: November 28, 2019
    Applicants: Institut Pasteur de Montevideo, Universidad de la República
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Paulina Invernizzi, Mariana Ingold, Lucia Colella
  • Use of AAC-11 inhibitors for the treatment of viral infection
    Patent number: 10463713
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of viral infection.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 5, 2019
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT-PARIS 7, INSTITUT PASTEUR
    Inventors: Jean-Luc Poyet, Asier Saez-Cirion, Heriberto Bruzzoni-Giovanelli, Leonard Jagot-Lacoussiere, Annie David, Anastassia Mikhailova
  • Method of culturing segmented filamentous bacteria in vitro
    Patent number: 10435665
    Abstract: The present invention relates to an in vitro method of culturing a segmented filamentous bacterium strain, comprising co-culturing said segmented filamentous bacterium strain with a eukaryotic host cell, wherein the culture is performed at an O2 level inferior to 5% in a rich tissue culture liquid medium containing bacterial medium components including iron. The present invention also relates to methods for genetically modifying a segmented filamentous bacterium strain comprising a step a culturing the strain in vitro.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: October 8, 2019
    Assignees: INSTITUT PASTEUR, FONDATION IMAGINE, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE PARIS DESCARTES
    Inventors: Eberl Gerard, Bikard David, Schnupf Pamela, Cerf Bensussan Nadine, Gaboriau-Routhiau Valerie, Sansonetti Philippe
  • MET receptor agonist proteins
    Patent number: 10435450
    Abstract: Disclosed are proteins derived from the HGF/SF which are able to induce activation of the tyrosine kinase receptor MET and their uses, in particular to promote tissue regeneration. Further disclosed are nucleic acid molecules coding such protein, expression vectors containing such nucleic acid molecule, host cells containing such expression vectors, and related compositions.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: October 8, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITA' DEGLI STUDI DI PAVIA, UNIVERSITÉ DE LILLE
    Inventors: Jerome Vicogne, Oleg Melnyk, Nathalie Ollivier, Eric Adriaenssens, Berenice Leclercq, Claire Simonneau, Giovanni De Nola, Ermanno Gherardi, Hugo De Jonge
  • Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions
    Patent number: 10428008
    Abstract: Nitroalkene non-steroidal anti-inflammatory compounds, pharmaceutical compositions thereof, and methods of treating inflammation related conditions.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: October 1, 2019
    Assignee: Institut Pasteur de Montevideo
    Inventors: Carlos Batthyány, Gloria Virginia López, Carlos Escande, Jorge Rodriguez Duarte, Williams Arturo Porcal Quinta, Rosina Dapueto Capuccio, Germán Adrian Galliussi López, María Pia Garat Nuñez, Paulina Invernizzi, Mariana Ingold, Lucia Colella
  • Methods and pharmaceutical compositions for the treatment of respiratory tract infections
    Patent number: 10426816
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 1, 2019
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut Pasteur de Lille
    Inventors: Jean-Claude Sirard, Jose A. Chabalgoity
  • Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
    Patent number: 10420827
    Abstract: The present invention relates to a life attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: September 24, 2019
    Assignees: Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Pasteur de Lille, National University of Ireland Maynooth
    Inventors: Camille Locht, Bernard Mahon, Heather Kavanaugh
  • Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
    Patent number: 10407695
    Abstract: The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: September 10, 2019
    Assignees: Institut Pasteur, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique
    Inventors: Pierre Charneau, Veronique Zennou, Francoise Pflumio, Aude Sirven, Anne Dubart Kupperschmitt
  • Vaccines for serogroup X meningococcus
    Patent number: 10376573
    Abstract: A method for immunizing a subject against serogroup X meningococcus by administering a vaccine comprising one, two or all three of: (i) a meningococcal fHbp antigen; (ii) a meningococcal NHBA antigen; and/or (iii) a meningococcal NadA antigen. The vaccine may also include meningococcal outer membrane vesicles.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: August 13, 2019
    Assignees: GlaxoSmithKline Biologicals SA, Institut Pasteur
    Inventors: Mariagrazia Pizza, Peter Dull, Marzia Monica Giuliani, Muhamed-Kheir Taha, Eva Hong, Ala-Eddine Deghmane